Source: Annual Congress 2003 - Work-related COPD - Organic dusts
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. A. Kolodkina, T. P. Ses, L. N. Novikova, G. P. Orlova (St Petersburg, Russia). Difference in immunological aspects of inflammation in idiopathic pulmonary fibrosis (IPF) and exogenous toxic alveolitis (ETA). Eur Respir J 2003; 22: Suppl. 45, 816

Member's Comments

No comment yet.

Related content which might interest you: Small airways impairment and air-trapping distinguish chronic hypersensitivity pneumonitis (CHP) from idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP) Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Cykine/receptor inflammatory profile in different types of idiopathic intestitial pneumonias (IIPs). Key role of Fas Ligand recruvation in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 The circulating metabolome in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD) Source: Eur Respir J 2004; 24: Suppl. 48, 533s Year: 2004 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 The similarity and difference of pathology of pulmonary arterioles in COPD and idiopathic lung fibrosis (IPF) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Markers of inflammation and pulmonary function (PF) in sarcoidosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Clinical physiology Year: 2006 Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006 Clinical significance of different cytokines expression in lung tissue in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 313s Year: 2002 Progressive fibrotic phenotype in exogenous toxic alveolitis (ETA) Source: Virtual Congress 2020 – Occupational exposure as a cause of respiratory disease Year: 2020 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Idiopathic pulmonary fibrosis (IPF) Source: ERS Course 2016 Year: 2016 Aerosolized interferon-gamma (IFN-γ) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007 Association between AGTTGFB1ESR1, and VDR gene variants with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis (PS) clinical features Source: International Congress 2017 – Functional genomics knowledge in parenchymal and bronchial diseases Year: 2017 The study of C5a complement component in patients with idiopathic pulmonary fibrosis, toxic fibrosing alveolitis and extrinsic allergic alveolitis Source: Eur Respir J 2001; 18: Suppl. 33, 108s Year: 2001 Enhanced effects of pirfenidone on the early phase of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009